Core Viewpoint - The article highlights the approval of the boron-10 injection by China's National Medical Products Administration, marking the entry into Phase I clinical trials for a novel cancer treatment method known as Boron Neutron Capture Therapy (BNCT) [1] Group 1: Drug Development - The boron-10 injection has received the Clinical Trial Approval Notification, allowing it to proceed to Phase I clinical trials [1] - The clinical cooperation project for BNCT is a joint effort involving China National Nuclear Corporation, Lanzhou University, Fujian Ruisi Technology, and Fujian Medical University Union Hospital [1] Group 2: Treatment Efficacy - BNCT is a targeted radiation therapy that shows promising results for recurrent, infiltrative, and locally metastatic tumors, particularly for recurrent gliomas, head and neck tumors, malignant melanomas, and malignant meningiomas [1] - Initial clinical trials have also shown effectiveness for other common cancers such as liver cancer, lung cancer, and prostate cancer [1] Group 3: Mechanism and Potential - The therapy's mechanism relies on the specific affinity of boron-10 compounds for cancer cells, which allows for targeted destruction of tumor cells while protecting surrounding healthy tissue [1] - The approval of the boron-10 injection is expected to accelerate the industrialization of BNCT, positioning it as a breakthrough direction in cancer treatment [1]